Ping Dong

Dr. Ping Dong


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Clinical Immunology
Verified
Journal Article
Closed access
LSLi-Song Shen
Li-Song Shen
JWJian Wang
Jian Wang
DSDing-Feng Shen
Ding-Feng Shen
XYXiang-Liang Yuan
Xiang-Liang Yuan
PDPing Dong
Ping Dong
DXDAKANG XU
DAKANG XU

1 January 2021 in International Journal of Biological Sciences
Verified
Journal Article
Open access
FLFeng-Nan Li
Feng-Nan Li
QZQin-Yi Zhang
Qin-Yi Zhang
OLOu Li
Ou Li
SLShi-Lei Liu
Shi-Lei Liu
ZYZi-Yi Yang
Zi-Yi Yang
PDPing Dong
Ping Dong
Background: Estrogen-related receptor-α (ESRRA) is an orphan nuclear receptor, expressing at high level in exuberant metabolism organs and acting as transcription factor. High expression was found in many malignances but no research was done in gastric cancer (GC), where lipid metabolism disorder is common.

8 August 2024 in Advanced Science
Verified
Journal Article
Open access
CZCheng Zhao
Cheng Zhao
JZJing‐Wei Zhao
Jing‐Wei Zhao
YZYu‐Han Zhang
Yu‐Han Zhang
YZYi‐Di Zhu
Yi‐Di Zhu
ZYZi‐Yi Yang
Zi‐Yi Yang
WGWei Gong
Wei Gong
Gallbladder cancer (GBC) is the most common malignant tumor of the biliary system, with poor response to current treatments. Abnormal alternative splicing has been associated with the development of a variety of tumors. Combining the GEO database and GBC mRNA‐seq analysis, it is found high expression of the splicing factor polypyrimidine region‐ binding protein 3 (PTBP3) in GBC. Multi‐omics analysis revealed that PTBP3 promoted exon skipping of interleukin‐18 (IL‐18), resulting in the expression of ΔIL‐18, an isoform specifically expressed in tumors. That ΔIL‐18 promotes GBC immune escape by down‐regulating FBXO38 transcription levels in CD8+T cells to reduce PD‐1 ubiquitin‐mediated degradation is revealed. Using a HuPBMC mouse model, the role of PTBP3 and ΔIL‐18 in promoting GBC growth is confirmed, and showed that an antisense oligonucleotide that blocked ΔIL‐18 production displayed anti‐tumor activity. Furthermore, that the H3K36me3 promotes exon skipping of IL‐18 by recruiting PTBP3 via MRG15 is demonstrated, thereby coupling the processes of IL‐18 transcription and alternative splicing. Interestingly, it is also found that the H3K36 methyltransferase SETD2 binds to hnRNPL, thereby interfering with PTBP3 binding to IL‐18 pre‐mRNA. Overall, this study provides new insights into how aberrant alternative splicing mechanisms affect immune escape, and provides potential new perspectives for improving GBC immunotherapy.

1 January 2021 in International Journal of Biological Sciences
Verified
Journal Article
Open access
SLShi-Lei Liu
Shi-Lei Liu
CCChen Cai
Chen Cai
ZYZi-Yi Yang
Zi-Yi Yang
ZWZi-You Wu
Zi-You Wu
XWXiang-Song Wu
Xiang-Song Wu
WGWei Gong
Wei Gong
Long noncoding RNA DiGeorge syndrome critical region gene 5 (DGCR5) has been shown to be highly associated with cancer development. However, the biological role and molecular mechanism of DGCR5 in pancreatic cancer (PC) remains largely unknown. This study aimed to explore the role of DGCR5 in PC. It was revealed that DGCR5 was highly expressed in PC tissues compared with adjacent normal tissues and was associated with poor prognosis in PC patients. Furthermore, DGCR5 depletion inhibited the proliferation, migration and invasion by increasing apoptosis and inducing G0/G1 cell cycle arrest in vitro. Moreover, xenograft assay validated that DGCR5 promotes PC tumor growth in vivo. Mechanistically, DGCR5 was found to act as a ceRNA by sponging miR-3163 to regulate DNA topoisomerase 2-alpha (TOP2A) and inhibit Wnt/β-catenin pathway. In addition, it was found that DGCR5 downregulation could enhance the sensitivity of PC cells to gemcitabine, and ChIP assay showed that PAX5 (Paired Box 5) could bind to the promoter region of DGCR5 and increase its transcription. The results of the present study indicated that DGCR5 may be a potential diagnostic biomarker and therapeutic target for PC.

19 June 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
SLShilei Liu
Shilei Liu
FLFengnan Li
Fengnan Li
LPLijia Pan
Lijia Pan
ZYZiyi Yang
Ziyi Yang
YSYijun Shu
Yijun Shu
WGWei Gong
Wei Gong
Gallbladder cancer (GBC) is the most common malignancy with high mortality of the bile duct. Here, we demonstrated BRD4 inhibitor JQ1 and histone deacetylase inhibitor SAHA synergistically inhibited the GBC cells in vitro and in vivo. Our results showed that cotreatment with JQ1 and SAHA significantly inhibited proliferation, cell viability, metastasis, and induced apoptosis and G2/M arrest in GBC cells, but only minor effects in benign cells. In vivo, tumor volumes and weights of GBC xenograft models were significantly decreased after treated with JQ1 or SAHA, meanwhile the cotreatment showed the strongest effect. Further study indicated that the above anticancer effects was associated with the downregulation of BRD4 and suppression of PI3K/AKT and MAPK/ERK pathways. These findings highlight JQ1 and SAHA as potential therapeutic agents and their combination as promising therapeutic strategy for GBC.

30 September 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CZCheng Zhao
Cheng Zhao
ZYZiyi Yang
Ziyi Yang
JZJian Zhang
Jian Zhang
OLOu Li
Ou Li
SLShi-Lei Liu
Shi-Lei Liu
PDPing Dong
Ping Dong
Background: Gallbladder cancer (GBC) is a highly aggressive malignant cancer in the biliary system with poor prognosis. XPO1 (chromosome region maintenance 1 or CRM1) mediates the nuclear export of several proteins, mainly tumor suppressors. Thus, XPO1 functions as a pro-oncogenic factor. KPT-330 (Selinexor) is a United States Food and Drug Administration approved selective inhibitor of XPO1 that demonstrates good therapeutic effects in hematologic cancers. However, the function of XPO1 and the effect of KPT-330 have not been reported in GBC. Methods: We analyzed the correlation between XPO1 expression levels by q-PCR and clinical features of GBC patients. Cell proliferation assays were used to analyze the in vitro antitumor effects of XPO1 inhibitor KPT-330. mRNA sequencing was used to explore the underlying mechanisms. Western blot was performed to explore the relationship between apoptosis and autophagy. The in vivo antitumor effect of KPT-330 was investigated in a nude mouse model of gallbladder cancer. Results: We found that high expression of XPO1 was related to poor prognosis of GBC patients. We observed that XPO1 inhibitor KPT-330 inhibited the proliferation of GBC cells in vitro. Furthermore, XPO1 inhibitor KPT-330 induced apoptosis by reducing the mitochondrial membrane potential and triggering autophagy in NOZ and GBC-SD cells. Indeed, XPO1 inhibitor KPT-330 led to nuclear accumulation of p53 and activated the p53/mTOR pathway to regulate autophagy-dependent apoptosis. Importantly, KPT-330 suppressed tumor growth with no obvious toxic effects in vivo. Conclusion: XPO1 may be a promising prognostic indicator for GBC, and KPT-330 appears to be a potential drug for treating GBC effectively and safely.